What is the difference between Ac-SDKP and Teduglutide?

Ac-SDKP: Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme. Teduglutide: GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Is Ac-SDKP FDA approved?

Ac-SDKP is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Teduglutide FDA approved?

Teduglutide is FDA approved (FDA status current as of 2012-12-21). This regulatory status is provided for research and educational context only.

How is Ac-SDKP administered in research settings?

In research settings, Ac-SDKP is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Teduglutide administered in research settings?

In research settings, Teduglutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Ac-SDKP vs Teduglutide

Peptide Comparison

Ac-SDKP vs Teduglutide

Both are Tissue Repair peptides.

Ac-SDKP

N-acetyl-seryl-aspartyl-lysyl-proline

RecoveryNot EvaluatedResearch Only

No providers listed yet

Full Ac-SDKP profile →

Teduglutide

Gattex

RecoveryFDA ApprovedPrescription

Half-life: ~2 hours

No providers listed yet

Full Teduglutide profile →

Bottom line

Teduglutide is FDA-approved, while Ac-SDKP is not evaluated — the clearest structural difference between them.

Quick Verdict

Ac-SDKP

Half-life

—

Teduglutide

Half-life

~2 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Teduglutide
Further along in FDA review	Teduglutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Ac-SDKP

Teduglutide

Mechanism Family

Tissue Repair

Half-life

—

~2 hours

FDA Status

not evaluated

approved

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Prescription

Providers

None listed

FDA Update

—

Dec 2012

Avail. Notes

—

FDA-approved GLP-2 analog. Brand: Gattex (NDA 203441, Dec 2012). Indicated for short bowel syndrome in adults and paediatric patients. Daily subcutaneous injection. Prescription only.

Research Evidence

Ac-SDKP

Animal · 3 key studies · most recent 2026

Teduglutide

Cohort study · 8 key studies · most recent 2026

Research Citations

Ac-SDKP

Animal2026 · Biomater Adv

Device surface-functionalized ac-SDKP nanoassemblies accelerate endothelial recovery through dual anti-inflam…

Animal2015 · American Journal of Physiology: Renal Physiology

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythe…

Animal2013 · Kidney International

Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis

Teduglutide

Cohort2026 · Clin Nutr

From childhood to adulthood in chronic intestinal failure: A nationwide study.

Case series2026 · JPGN Rep

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

Cohort2026 · Clin Nutr

Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment.

Cohort2026 · Clin Nutr ESPEN

Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure.

+4 more

About Ac-SDKP

Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.

Research Areas

anti-fibroticcardiac repairwound healingkidney protection

About Teduglutide

GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Research Areas

intestinal growthgut repairabsorptive surface restorationshort bowel syndrome treatment

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Ac-SDKP

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Teduglutide

Reported (Unverified — Pending Clinical Review)

GI malignancy or historycolorectal polyps (monitor)

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Ac-SDKP

Browse directory →

Providers offering

Teduglutide

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.